13F reference period
Q2 2026
Security Snapshot
MapLight Therapeutics, Inc. - Common Stock, par value $0.0001 per share (MPLT) Institutional Ownership
CUSIP: 56565P103
13F Institutional Holders and Ownership History from Q4 2025 to Q3 2026
Institutions Reporting
104
Shares (Excl. Options)
26.26M
Full value: 26,255,287 · shares · 30 Jun 2026Price
$35.84
The headline uses the Q2 2026 reference period after its reporting deadline. Available reports may still be incomplete or amended. Newer periods in the history table contain incoming reports and may be incomplete.
Save this security page for your next review
Watchlists follow companies and investors, across their share classes. Bookmark this page to revisit this specific CUSIP and its quarterly holders. If you create an account from here, we will bring you back after verification.
- Security type / class
- Equity / Common Stock, par value $0.0001 per share
- Symbol
- MPLT on Nasdaq
- All holders as of 30 Jun 2026
- Q2 2026
- Total 13F shares
- 26,255,287
- Total 13F value
- $940,985,727
- Portfolio coverage rank
- 0%
- Share change
- +1,576,403
- Value change
- +$72,494,124
- Number of holders
- 104
- Shares outstanding
- 53,015,891
- SEC-reported price per share
- $10.19
- Insider filing price
- $10.19
Latest holder snapshot
5 signals
Issuer context
Names, identifiers, and filing context for this profile.
3 identity fields
13F Shares, Excluding Options vs Price
13F Value, Excluding Options
Total Investors
Filing notes and source
Key facts
- MPLT - MapLight Therapeutics, Inc. - Common Stock, par value $0.0001 per share is tracked under CUSIP 56565P103.
- 104 institutions reported positions in Q2 2026.
- 5 significant owners is listed from Schedule 13D/13G reporting.
Change
- Holder count moved from 80 to 104 between Q1 2026 and Q2 2026.
- SEC-reported value moved from to
$502.15M
Full value: $502,152,842 · USD · 31 Mar 2026.$940.99M
Full value: $940,985,727 · USD · 30 Jun 2026
Research use
- You can quickly see who holds this security, then open quarter and manager detail pages for full evidence.
- 13F and Schedule 13D/13G sections are kept together so you can cross-check institutional and beneficial ownership context.
Evidence
Source: SEC Form 13F
Open SEC evidence
Latest holder context comes from 104 institutions filings for Q2 2026.
Security key
56565P103
13F reference period
Q2 2026
13F holders
104
13D/G owners
5
CIK / CUSIP context first
Open Q2 2026 holders
MPLT full holder history
MapLight Therapeutics, Inc. SEC filings
MapLight Therapeutics, Inc. company facts
MapLight Therapeutics, Inc. insider transactions
Broader feeds
Recent Quarterly Holder Reports
Open recent reporting periods for CUSIP 56565P103:
13D/G owners
Significant owners
Large-stake holder rows connected to Schedule 13D/G evidence.
Rows
5
Security
MPLT
| Filer | Ownership | Change % | Holdings Value | Net Change | Nb Shares | Change % | Reporting Name | Report Period |
|---|---|---|---|---|---|---|---|---|
| Catalyst4, Inc. | 50% | +4.2% | $386,330,234 | +$93,009,388 | 27,536,011 | +32% | Catalyst4, Inc. | 14 Aug 2026 |
| Forbion Growth Opportunities Fund III Cooperatief U.A. | 7.1% | $61,527,448 | 3,226,400 | Forbion Growth Opportunities Fund III Cooperatief U.A. | 31 Dec 2025 | |||
| T. Rowe Price Investment Management, Inc. | 7.4% | +20% | $83,866,925 | +$9,044,844 | 3,137,558 | +12% | T. Rowe Price Investment Management, Inc. | 31 Mar 2026 |
| Pivotal bioVenture Partners Fund II, L.P. | 5.5% | $40,909,712 | 2,915,874 | Nan Fung Group Holdings Limited | 13 Aug 2026 | |||
| Novo Holdings A/S | 4.9% | -44% | $76,307,767 | -$58,512,000 | 2,086,622 | -43% | Novo Holdings A/S | 30 Jul 2026 |
As of 30 Jun 2026,
104
institutional investors reported holding
shares of
MapLight Therapeutics, Inc. - Common Stock, par value $0.0001 per share (MPLT).
This represents
50%
of the company’s total
outstanding shares.
26.26M
Full value: 26,255,287 · shares · 30 Jun 202653.02M
Full value: 53,015,891 · shares · Stored outstanding share count13F concentration
Top 25 institutional shareholders
Largest 13F positions for this security by reported shares and value.
Top holder share
46%
| Institution | Ownership % | Shares Held | Share Change % | Portfolio % | Holdings Value |
|---|---|---|---|---|---|
| NOVO HOLDINGS A/S | 7% | 3,686,622 | 0% | 7.7% | $132,128,532 |
| FCPM III SERVICES B.V. | 6.1% | 3,226,400 | 0% | 15% | $115,634,176 |
| T. Rowe Price Investment Management, Inc. | 5.2% | 2,781,728 | -0.72% | 0.07% | $99,698,000 |
| GOLDMAN SACHS GROUP INC | 3.7% | 1,948,312 | -2.3% | 0.01% | $69,827,502 |
| PRICE T ROWE ASSOCIATES INC /MD/ | 2.7% | 1,422,935 | +1162% | 0.01% | $50,999,000 |
| BlackRock, Inc. | 1.9% | 1,025,134 | -23% | 0% | $36,740,802 |
| Nan Fung Group Holdings Ltd | 1.8% | 971,253 | 0% | 26% | $34,809,708 |
| 5AM Venture Management, LLC | 1.8% | 950,011 | 0% | 12% | $34,048,394 |
| Sanofi | 1.7% | 912,041 | 0% | 6.1% | $32,687,549 |
| STATE STREET CORP | 1.6% | 852,150 | +151% | 0% | $30,541,056 |
| FMR LLC | 1.6% | 823,556 | +303% | 0% | $29,516,247 |
| VANGUARD CAPITAL MANAGEMENT LLC | 1.5% | 784,150 | +8.9% | 0% | $28,103,936 |
| Blue Owl Capital Holdings LP | 1.4% | 729,929 | -27% | 4% | $26,160,655 |
| Paradigm Biocapital Advisors LP | 1.3% | 685,852 | 0.46% | $24,580,936 | |
| Pivotal bioVenture Partners Investment Advisor LLC | 1.2% | 611,446 | -0% | 7.1% | $21,914,225 |
| Velan Capital Investment Management LP | 0.93% | 492,893 | 0% | 11% | $17,665,285 |
| Siren, L.L.C. | 0.85% | 450,000 | 0% | 0.33% | $16,128,000 |
| Capital World Investors | 0.78% | 415,730 | 0% | $14,899,763 | |
| GEODE CAPITAL MANAGEMENT, LLC | 0.76% | 402,051 | -16% | 0% | $14,414,363 |
| BAKER BROS. ADVISORS LP | 0.69% | 364,705 | 0% | 0.07% | $13,071,027 |
| DAFNA Capital Management LLC | 0.32% | 171,006 | 0% | 1.2% | $6,128,855 |
| BNP PARIBAS ASSET MANAGEMENT Holding S.A. | 0.32% | 170,862 | -36% | 0.01% | $6,123,694 |
| Freestone Grove Partners LP | 0.32% | 168,912 | -46% | 0.04% | $6,053,806 |
| CHARLES SCHWAB INVESTMENT MANAGEMENT INC | 0.26% | 136,818 | -15% | 0% | $4,903,557 |
| MILLENNIUM MANAGEMENT LLC | 0.24% | 128,841 | 0% | $4,617,661 |
Quarter history
Institutional holders across reporting periods
Holder count, reported shares/value, and median price by quarter.
Periods
4
Headline period
Q2 2026
Rows shown
1-4 of 4
| Period | 13F Shares, Excl. Options | Value, Excl. Options | Value Change | Price (Median) | Investors |
|---|---|---|---|---|---|
| 2026 Q3 | 16,721 | $170,388 | -$50,516 | $10.19 | 7 |
| 2026 Q2 | 26,255,287 | $940,985,727 | +$72,494,124 | $35.84 | 104 |
| 2026 Q1 | 24,700,477 | $502,152,842 | +$34,264,805 | $20.33 | 80 |
| 2025 Q4 | 23,065,711 | $405,121,994 | +$405,061,184 | $17.56 | 74 |